<DOC>
	<DOCNO>NCT01065935</DOCNO>
	<brief_summary>To evaluate efficacy safety ALN-RSV01 plus standard care RSV infect lung transplant patient</brief_summary>
	<brief_title>Phase 2b Study ALN-RSV01 Lung Transplant Patients Infected With Respiratory Syncytial Virus ( RSV )</brief_title>
	<detailed_description />
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
	<criteria>Single bilateral lung transplant recipient Confirmed RSV infection Greater 90 day post current lung transplant Rejection free minimum 30 day Known viral , bacterial , fungal respiratory coinfection time RSV diagnosis Bronchiolitis obliterans syndrome ( BOS ) Grade 3 BOS FEV1 stable least 3 month Use alemtuzumab within 9 month prior screen , antithymocyte globulin ( ATG ) within 90 day screen prednisone equivalent maintenance therapy Active treatment acute graft rejection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>ALN-RSV01</keyword>
	<keyword>RSV</keyword>
	<keyword>Respiratory Syncytial Virus</keyword>
</DOC>